Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study.

Date publication

octobre 2024

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher , Pr BOUCHE Olivier

Tous les auteurs :
M'Baloula J, Tougeron D, Boilève A, Jeanbert E, Guimbaud R, Ben Abdelghani M, Durand A, Turpin A, Quesada S, Blanc JF, Artru P, Toullec C, Trouilloud I, Pellat A, Touchefeu Y, Pinot J, Caroli-Bosc FX, Taïeb J, Doat S, Bouché O, Védie AL, de Mestier L, Muller M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39366210

Résumé

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. The POLO trial showed that olaparib (PARP inhibitor) improved progression-free survival (PFS) but not overall survival (OS), when used as maintenance therapy after ≥ 16 weeks of disease control with first-line platinum-based chemotherapy in patients with germline (g) BRCA 1 or 2 pathogenic variants (PV) metastatic PDAC. However, real-world data on the effectiveness of olaparib are missing.

Mots clés

(MeSH terms), BRCA, Hereditary neoplastic syndromes, Homologous recombination deficiency, PARP inhibitor, Pancreatic ductal adenocarcinoma

Référence

Eur J Cancer. 2024 10 1;212:115051